Dr. G. F. Pacelli 1, L. Baraggia 1, Dr.ssa B. Pacelli 2, Dr. V. Ferrara 1, Dr. V. Belloli 1 Microperimetric follow-up (FU) of clinical significant diabetic.

Slides:



Advertisements
Similar presentations
TESTUPLOAD. TORSIONAL PHACOEMULSIFICATION In January 2006 Alcon Surgical incorporated Ozil torsional into the Infiniti Vision System. Unlike the conventional.
Advertisements

The Diabetic Retinopathy Clinical Research Network
A Comparison between Fluorescein Angiography and Optical Coherence Tomography Findings in Patients with Clinically Significant Macular Edema KoriAnne Elkins.
UCL Institute of Ophthalmology Department of Genetics
LOW FLUENCE PHOTODYNAMIC THERAPY (PDT-BF) IN CHRONIC CENTRAL SEROUS CHORIORETINOPATY (CSC): SD-OCT EVOLUTION AND ITS FUNCTIONAL IMPACT. LOW FLUENCE PHOTODYNAMIC.
CATARACT SUEGRY AND DIABETES Indications of surgery: 1) Visual loss 2)Surveillance of retinopathy 3)Laser therapy.
Oct interpretation Ghanbari MD This is what we wanted.
Are Network Results Regarding Ocular Coherence Tomography (OCT) Relevant to Clinical Practice and Clinical Trials? Sponsored by the National Eye Institute,
IMAGING in AMD From Fluorescein Angiography To the Spectral Domain OCT
Vitrectomy Outcomes in Eyes with Diabetic Macular Edema, Visual Loss, and Vitreomacular Traction Sponsored by the National Eye Institute, National Institutes.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Macular Edema After Cataract Surgery Diabetic Retinopathy Clinical Research Network.
Diabetic Retinopathy Steven Sanislo, M.D. Assistant Professor Stanford University Department of Ophthalmology.
Interpretation of SD-OCT Gella Laxmi 2009PHXF013P.
The Diabetic Retinopathy Clinical Research Network Comparison of Visual and OCT Outcomes in Eyes with and without Prior Vitrectomy Receiving Anti- Vascular.
Diabetes and the Eyes Kenyon Anderson, O.D.. Blindness Risk Diabetic eye disease, caused by diabetes, is a leading cause of blindness and vision loss.
The Diabetic Retinopathy Clinical Research Network 5-Year Follow-up of a Randomized Trial Evaluating Ranibizumab Plus Prompt versus Deferred Laser for.
Factors Associated with Changes in Visual Acuity and OCT Thickness at 1 Year after Treatment for Diabetic Macular Edema Sponsored by the National Eye Institute,
European Association for Vision and Eye Research – Crete, Oct 5-8, 2011 Ranibizumab for the Treatment of Exudative Age-Related Macular Degeneration Associated.
The Diabetic Retinopathy Clinical Research Network
Luu CD, Dimitrov PN, Robman L, et al. Role of flicker perimetry in predicting onset of late-stage age-related macular degeneration. Arch Ophthalmol. 2012;130(6):
The Diabetic Retinopathy Clinical Research Network Protocol I: Clinical Applications Supported through a cooperative agreement from the National Eye Institute.
Laser-Ranibizumab-Triamcinolone for DME Study DRCR.net Protocol I
Phase IIIb Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration PIER Study Year 1 Regillo CD,
Diagnosis & Management of Diabetic Eye Disease A. Paul Chous, M.A., O.D., F.A.A.O. Tacoma, WA Specializing in Diabetes Eye Care & Education Part 6.
Anterior Segment Optical Coherence Tomography and In Vivo Confocal Microscopy Findings in Femtosecond Laser- Assisted Keratoplasty Kurt H. Kelley, MD;
Effect of Corneal Thickness on Selective Laser Trabeculoplasty to Decrease Intraocular Pressure as Primary or Secondary Treatment of Glaucoma ASCRS 2010.
Comparison of Modified ETDRS and Mild Macular Grid Laser Photocoagulation Strategies for Diabetic Macular Edema Sponsored by the National Eye Institute,
A Randomized Trial of Peribulbar Triamcinolone Acetonide with and without Focal Photocoagulation for Mild Diabetic Macular Edema: A Pilot Study.
The Diabetic Retinopathy Clinical Research Network What is the Role of Laser In Treating Diabetic Macular Edema in the Era of Anti-VEGF Therapy? 1.
OCT in Amblyopia Lionel Kowal.
Optical Coherence Tomography (OCT) Gella Laxmi 2009PHXF013P.
The Diabetic Retinopathy Clinical Research Network
Prospective, Randomized, Double-Blind Study Comparing Nepafenac 0.1% (Nevanac™) and Bromfenac Sodium 0.09% (Xibrom™) in Post-Op Cataract Patients Hon-Vu.
Update on Prevention, Diagnosis & Treatment of Diabetic Macular Edema (DME) Part 1 A. Paul Chous, MA, OD, FAAO Specializing in Diabetes Eye Care & Education.
Update on Prevention, Diagnosis & Treatment of Diabetic Macular Edema (DME) Part 2 A. Paul Chous, MA, OD, FAAO Specializing in Diabetes Eye Care & Education.
RETINOPATHY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Effect of Race on Selective Laser Trabeculoplasty  1st author has no financial interest in the subject matter of this poster.  2nd and 3rd co-authors.
Introduction  Selective Laser Trabeculoplasty (SLT) uses a Q-Switched frequency- doubled (532 nm), low energy Nd:YAG laser, which targets melanocytes.
The Diabetic Retinopathy Clinical Research Network
Sponsored by the National Eye Institute,
Chronic Visual Loss. CHRONIC VISUAL LOSS 1. Measure intraocular pressure with a tonometer 2. Evaluate the nerve head 3. Evaluate the clarity of the lens.
Effect of East Asian Race on Selective Laser Trabeculoplasty ASCRS 2011 Minerva Kim Johns Hopkins University Lawrence F. Jindra, MD Columbia University.
Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health.
Effect of Refractive State on Selective Laser Trabeculoplasty ASCRS 2011 Kevin Lai Stony Brook University School of Medicine Elaine M. Miglino Floral Park.
Central serous chorioretinopathy and uveitis Central serous chorioretinopathy and uveitis Rim Kahloun, MD Sonia Zaouali, MD Moncef Khairallah, MD Moncef.
COMPARATIVE EFFICACY OF INTRAVITREAL BEVACIZUMAB AND RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR OEDEMA J.A. Montero, J.M. Ruiz-Moreno VISSUM, Alicante.
Six-Year Longevity of Selective Laser Trabeculoplasty as Primary Therapy in Patients with Glaucoma ASCRS 2009 Lawrence F. Jindra, MD Columbia University.
Effect of Previous Argon Laser Trabeculoplasty on Selective Laser Trabeculoplasty ASCRS 2011 Lawrence F. Jindra, MD Columbia University Winthrop University.
Liquifaction Method and Extent of Posterior Capsule Opacification: Two-Year Follow-up Marie Kalfertova, Mariya Burova, Pavel Rozsival, Nada Jiraskova Nada.
Rapid unusual reasorbtion of drusenoid subfoveal lesions in AMD and pseudovitelliform maculopathy documented with SD-OCT and autofluorescence. Giorgio.
The Diabetic Retinopathy Clinical Research Network
PROPHYLAXIS OF MACULAR EDEMA WITH PEROPERATIVE INTRAVITREAL BEVACIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY UNDERGOING PHACOEMULSIFICATION; A RANDOMIZED.
Reproducibility of retinal thickness measurements in eyes with
A Paul, C Louize,S Shafquat Dudley Hospitals NHS Foundation Trust
Role of vitrectomy the treatment of diabetic macular edema
Correlation between visual acuity
Correlation between Deep Capillary Plexus Perfusion and Long-Term Photoreceptor Recovery after Diabetic Macular Edema Treatment  Byung Gil Moon, MD, Taewoong.
INTRAVITREAL INJECTION OF
Asymmetry Analysis of Retinal Thickness
당뇨황반부종에서의 레이저 치료 의정부 성모병원 안과 양지욱.
Modern retinal laser therapy
Protocol U Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involved DME Following Anti-VEGF.
F.Fazel,MD. F.Fazel,MD The treatment of Diabetic Retinopathy.
J. Fernando Arevalo, MD FACS Clínica Oftalmológica Centro Caracas
The Diabetic Retinopathy Clinical Research Network
Detecting Glaucoma Progression Using Guided Progression Analysis with OCT and Visual Field Assessment in Eyes Classified by International Classification.
Age-related Macular Degeneration (AMD)
DRCR Retina Network Treatment for Center-Involved DME in Eyes with Good Visual Acuity (Protocol V)
Multiple Evanescent White Dot Syndrome (MEWDS)
Presentation transcript:

Dr. G. F. Pacelli 1, L. Baraggia 1, Dr.ssa B. Pacelli 2, Dr. V. Ferrara 1, Dr. V. Belloli 1 Microperimetric follow-up (FU) of clinical significant diabetic macular edema (CSDME) after modified grid laser (MGL) treatment with Pascal laser (PL). 1 Polo Ospedaliero SS. Trinità Arona (No). Italy 2 Agenzia sanitaria e sociale. Regione Emilia Romagna. Unità Epidemiologia. Italy

CSDME: Increased Macular Thickness (MT) within 500 μm from the fovea, that often leads to an irreversible deterioration of visual acuity. CSDME: Increased Macular Thickness (MT) within 500 μm from the fovea, that often leads to an irreversible deterioration of visual acuity. Laser still remains the standard treatment and the only one with proven longstanding efficacy as shown by E.T.D.R.S. Studies. The Main limit of conventional ETDRS laser treatment is the potential impact on Macular Sensitivity (MS). Recently new laser treatment modalities have been developed in order to minimize the impact on deeper retinal layers (Among these PL seems to be promising ). Introduction:

Index of efficacy: Reduction in Retinal Thickness of the treated and the foveal area (SD-OCT RMT analysis). Reduction in Retinal Thickness of the treated and the foveal area (SD-OCT RMT analysis). The improvement of Foveal Sensitivity (FS). (MP1 analysis). The improvement of Foveal Sensitivity (FS). (MP1 analysis). Index of Safety: Improvement/stability of Retinal Sensitivity (RS) in the macula and particularly in the quadrant mainly exposed to PL. Improvement/stability of Retinal Sensitivity (RS) in the macula and particularly in the quadrant mainly exposed to PL. Main goal: To assess the efficacy of PASCAL MGL in the treatment of CSDME and its relative impact on MS. Microperimetry (MP1) is an optimal tool to assess the impact of laser on macular function. Secondary aim : To compare PL structural and functional effects with those shown by a similar previous study (28 eyes of 27 patients; mean FU 7 mos) conducted with conventional Longer Pulse Duration Laser (LPDL) using light treshold parameters (540 nm diode). Objective:

Side effects of Laser Photocoagulation are: Scotoma V-R Interface wrinkling Epiretinal pathology of vitreomacular traction syndrome A Gandorfer, M Rohleder, A Kampik Br J Ophthalmol 2002 Damage to the neurons (photoreceptors, bipolar and ganglions cells)

Effect of Pulse Duration on Size and Character of the Lesion in Retinal Photocoagulation. ATul Jain et al. Arch. Ophthalmol The Pascal® Sistem: Reduced Fluence (thermal energy delivered) Laser light is converted into heat, as it’s absorbed by the melanin and hemoglobin, in its tissutal target that is Retina Pigment epithelium (RPE). Combination of short duration and uniform pulses, typical of PL, has important effects in sparing photoreceptorial cells (PRC). With PL, less thermal energy spreads in all directions, heating less volumes of tissue as demonstrated by histology: 1.Less lateral heat diffusion: Less RPE and PRC damage. 2.Decreased anterior spread of heat: Less damage to inner retina and nerve fiber layer. Conventional Laser 200 ms;Ø 200 µm Power 175 mW = Fluence 84 J/cm 2 PASCAL ® 20 ms;Ø 200 µm Power 300 mW = Fluence 19 J/cm2 Histological appearance of lesions.

Materials and Methods: CSDME: 31 eyes of 26 consecutive patients (onset < 6 months ; 14 ♂ e 12 ♀ ; mean age 66 yrs; Mean FU: 8,3 mos). CSDME: 31 eyes of 26 consecutive patients (onset < 6 months ; 14 ♂ e 12 ♀ ; mean age 66 yrs; Mean FU: 8,3 mos). 2 groups ( Hba1c cut-off value: 9% ). 2 groups ( Hba1c cut-off value: 9% ). Group 1 ( Hb> 9% ): 11 patients (7 ♀ 4 ♂ ). Group 2 ( Hb<9% ): 15 patients (6 ♀ 9 ♂ ). Basal and quarterly evaluation of: BCVA log (ETDRS charts). BCVA log (ETDRS charts). SD-OCT RMT Spectralis (Heidelberg ing. Germany) SD-OCT RMT Spectralis (Heidelberg ing. Germany) MP1 central 20° (Nidek Tech., Vigonza PD, Italy). MP1 central 20° (Nidek Tech., Vigonza PD, Italy). Fluorescein angiography Spectralis (Heidelberg Ing. Germany). Fluorescein angiography Spectralis (Heidelberg Ing. Germany). PASCAL laser using single spot modality (Mean of 2 treatments). PASCAL laser using single spot modality (Mean of 2 treatments). Statistical significance (SS*) of trend comparing the initial with the very last control value Wilcoxon test for related samples.For each FU step, mean values for all parameters have been compared Mann Withney Test for independent sample. Statistical significance (SS*) of trend, overall and for each group, evaluated comparing the initial with the very last control value for each patient, applying Wilcoxon test for related samples. For each FU step, mean values for all parameters have been compared between groups by performing Mann Withney Test for independent sample. (*SS evaluated at α level of 0.05 and of 0.001).

Pseudophakic/mild lens opacities eyes* were included (eyes recently operated of phacoemulsification were excluded). Pseudophakic/mild lens opacities eyes* were included (eyes recently operated of phacoemulsification were excluded). Eyes affected by other chronic diseases were obviously excluded. Eyes affected by other chronic diseases were obviously excluded. Materials and Methods: * In case of cataract worsening follow-up was interrupted at the previous control.

ETDRS modified technique”: direct FL of microaneurisms and a MGL applied to the whole area of thickened retina.* (Mean Ø spot 65 μm) with a power limited to obtain a mild whitening effect (mean 60 m.W), 0.2 m.sec* ( Olk et al.Ophthalmology 90). ETDRS modified technique”: direct FL of microaneurisms and a MGL applied to the whole area of thickened retina.* (Mean Ø spot 65 μm) with a power limited to obtain a mild whitening effect (mean 60 m.W), 0.2 m.sec* ( Olk et al.Ophthalmology 90). Conventional LPDL (540 nm diode, 0.2 msec)

Short pulse duration PL (0.02 msec) ETDRS modified technique”: direct PL of microaneurisms and a MGL applied to the whole area of thickened retina.* (Mean Ø spot 60 μm) with a power limited to obtain a mild whitening effect (mean 175 m.W), 0.02 m.sec* ( Olk et al. Ophthalmology 90). ETDRS modified technique”: direct PL of microaneurisms and a MGL applied to the whole area of thickened retina.* (Mean Ø spot 60 μm) with a power limited to obtain a mild whitening effect (mean 175 m.W), 0.02 m.sec* ( Olk et al. Ophthalmology 90).

SD OCT ( LPDL ETDRS versus PL spots). LPDL PL

Conventional laser scar “Pascal” Laser scar “Pascal” Laser scar “Pascal” laser Scars Conventional L scar SD OCT ( LPDL ETDRS versus PL spots).

Pre PL CRT map Pre PL FA Post PL CRT map & Autofluorescence Short pulse duration PL (0.02 msec) Short pulse duration PL (0.02 msec) PL scar after 6 months

MP1 follow up (8 mos) of DME treated with PL.

Mean % increment in BCVA: 59 % (P<0.001). Increment in 93,5% of cases. Mean % increment in BCVA: 59 % (P<0.001). Initial BCVA: 0.32 log.;Final BCVA: 0.12 log. Differences between groups don’t achivies SS; Increment in 93,5% of cases. BCVA variations (ETDRS Chart) Foveal Sensitivity (Db). Mean % increment of FS: 21%. (P<0.001). Increment in 77,42 % of cases Mean % increment of FS: 21%. (P<0.001). Initial FS: 10,92 db; Final FS: 12,58 db. Differences between groups don’t achivies SS at 9 mos. Increment in 77,42 % of casesResults:

Results: Mean % increment of RS in the quadrant: 13% (P<0.001) Initial Mean RS: 11,24 db.; Final mean RS:12.42 db. Increment in 77,42 % of cases After 9 mos the differences between groups don’t achivies SS. Increment in 77,42 % of cases Mean % increment of RS: 8%. (P<0.002). Initial mean RS is 10.6; final 11.8 db. After 9 mos the differences between groups don’t achivies SS. Increment :64,5% of cases. RS in the area mainly exposed to PL RS in the central 20° macula

Central 20° RT Central RT (3 mm) Mean % decrease of MT: 17 % (P<0,001) Initial MT: 406,1 micron.;Final MT: 359,3 micron Differences between groups don’t achivies SS Decrement in 90,3% of cases. Mean % decrease of CRT: 15 %. (P<0,001) Initial MT: 436,86 micron; Final MT: 383,2 micron Differences between groups don’t achivies SS Decrement in 93,5% of cases. Mean % decrease of sectorial RT :17% (P<0,001). Initial MT: 406,1 micron; Final MT: 359,3 micron Decrement in 93,5% of cases Differences between groups don’t achivies SS Decrement in 93,5% of cases. Results: RT of sector mainly exposed to PL

Conventional LPDL SPDL (Pascal) FS 30% Initial Value (IV):11.4 Db; Final value (FV):14.9 Db 21% (IV:10.9 Db; FV:12.5 Db). RS sector 24% IV: 10.6 Db; FV: 11.8 Db. 13% IV: 11,24 Db.; FV:12.42 Db. CRT 9% IV: 330,8; FV: 285,4 micron. 15% IV: 436,86; FV: 383,2 micron SRT 14% IV: 343,7 FV:286,2 micron. 17% IV: 406,1; FV: 359,3 micron BCVA 36% IV: 0,19; FV:0,03 logmar 59% (IV: 0.32; FV :0.12 logmar Finally comparing PL (0,02 msec) results at 9 months with those of a previous study conducted in Focal diabetic macular edema treated with LPDL (diode: 540 nm 0,2 msec) using light parameters, we have to puntualize that macular edema were less diffuse (sectorial) and less intense than in this new study and this might explain the better result of the former study on FS evolution. PL versus 540 nm longer pulse duration laser (LPDL):

Conclusions: In the Era of anti-VEGF therapies, FL treatment remains the only with proven longstanding efficacy in the management of DME, expecially if light sub-threshold parameters are employed as with PL. ( Always a better trend in G2 for each parameter even if not always SS). In the Era of anti-VEGF therapies, FL treatment remains the only with proven longstanding efficacy in the management of DME, expecially if light sub-threshold parameters are employed as with PL. ( Always a better trend in G2 for each parameter even if not always SS). MP1 FU shows the absence of any MS impairment. MP1 FU shows the absence of any MS impairment. PL, minimizing laser scar, can be considered effective and safe. PL, minimizing laser scar, can be considered effective and safe. Concluding PL is a valid instrument to perform MGL: results similar to LPDL with less structural and functional impact on photoreceptorial layers. Concluding PL is a valid instrument to perform MGL: results similar to LPDL with less structural and functional impact on photoreceptorial layers. Limits of this study: The Difference in baseline severity of CSDME in our two studies doesn’t allow a reliable direct comparison beetwen PL and LPDL.The Difference in baseline severity of CSDME in our two studies doesn’t allow a reliable direct comparison beetwen PL and LPDL.

Bibliography: Photocoagulation for Diabetic Macular Edema (DME). ETDRS report number 1. Archives of Ophthalmology Photocoagulation for Diabetic Macular Edema (DME). ETDRS report number 1. Archives of Ophthalmology Treatment techniques and clinical guidelines for photocoagulation of DME. ETDRS Study report n° 2 Ophthalmology Treatment techniques and clinical guidelines for photocoagulation of DME. ETDRS Study report n° 2 Ophthalmology Striph GG, Hart WM Jr, Olk RJ. Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Ophthalmology 1988;95:1673–9. Striph GG, Hart WM Jr, Olk RJ. Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Ophthalmology 1988;95:1673–9. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse DME. Long-term visual results. Ophthalmology 1991;98:1594–602. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse DME. Long-term visual results. Ophthalmology 1991;98:1594–602. Hee MR, Puliafito C, Duker JS, et al. Topography of DME with OCT. Ophthalmology 1998;105:360–70. Hee MR, Puliafito C, Duker JS, et al. Topography of DME with OCT. Ophthalmology 1998;105:360–70. Sinclair SH, Alaniz R, Presti P. Laser treatment of DME: comparison of ETDRS-level treatment with threshold-level treatment by using high-contrast discriminant central visual field testing. Sem Ophthalmol 1999;4:214–22. Sinclair SH, Alaniz R, Presti P. Laser treatment of DME: comparison of ETDRS-level treatment with threshold-level treatment by using high-contrast discriminant central visual field testing. Sem Ophthalmol 1999;4:214–22. F Bandello, A Polito, M Del Borrello, N Zemella and M Isola. “Light” versus “classic” laser treatment for CSDME. Br. J. Ophthalmol. 2005;89; F Bandello, A Polito, M Del Borrello, N Zemella and M Isola. “Light” versus “classic” laser treatment for CSDME. Br. J. Ophthalmol. 2005;89; Schatz H, Madeira D, McDonald HR, et al. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse DME. Arch Ophthalmol 1991;109:1549 –1551. Schatz H, Madeira D, McDonald HR, et al. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse DME. Arch Ophthalmol 1991;109:1549 –1551. Luttrul JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of CSDMEBr J Ophthalmol 2005; 89:74 – 80. Luttrul JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of CSDME. Br J Ophthalmol 2005; 89:74 – 80. Jain A, Blumenkranz MS, Paulus Y, et al. Effect of pulse duration on size and character of the lesion in retinal photocoagulation. Arch Ophthalmol 2008;126:78–85. Jain A, Blumenkranz MS, Paulus Y, et al. Effect of pulse duration on size and character of the lesion in retinal photocoagulation. Arch Ophthalmol 2008;126:78–85. Framme C, Walter A, Prahs P, et al. Structural changes of the retina after conventional laser photocoagulation and selective retina treatment (SRT) in spectral domain OCT. Curr Eye Res 2009;34:568 –579. Framme C, Walter A, Prahs P, et al. Structural changes of the retina after conventional laser photocoagulation and selective retina treatment (SRT) in spectral domain OCT. Curr Eye Res 2009;34:568 –579. Figueira J et al. Prospective randomised controlled trial comparing sub-threshold micropulse laser photocoagulation and conventional green laser for CSDME. Br J Ophthalmol. 2009; 93: Figueira J et al. Prospective randomised controlled trial comparing sub-threshold micropulse laser photocoagulation and conventional green laser for CSDME. Br J Ophthalmol. 2009; 93: Blumenkranz MS, Yellachich D, Andersen DE. Semiautomated patterned scanning laser for retinal photocoagulation. Retina. 2006; 26: Blumenkranz MS, Yellachich D, Andersen DE. Semiautomated patterned scanning laser for retinal photocoagulation. Retina. 2006; 26: Kriechbaum K, Bolz M, Deak G, Prager S, Scholda C, Schmidt-Erfurth U. High-Resolution Imaging of the human retina in vivo after scatter photocoagulation treatment using a semiautomated laser system. Ophtalmology 2010, in press. Kriechbaum K, Bolz M, Deak G, Prager S, Scholda C, Schmidt-Erfurth U. High-Resolution Imaging of the human retina in vivo after scatter photocoagulation treatment using a semiautomated laser system. Ophtalmology 2010, in press.

Thank you ! Au revoir Paris